Treatment of Infection and Inflammation Associated with COVID-19, Multi-Drug Resistant Pneumonia and Fungal Sinusitis by Nebulizing a Nanosilver Solution

Solutions containing Ag0 nanoclusters, Ag+1, and higher oxidation state silver, generated from nanocrystalline silver dressings, were anti-inflammatory against porcine skin inflammation. The dressings have clinically-demonstrated broad-spectrum antimicrobial activity, suggesting application of nanosilver solutions in treating pulmonary infection.Nanosilver solutions were tested for antimicrobial efficacy;against HSV-1 and SARS-CoV-2;and nebulized in rats with acute pneumonia. Patients with pneumonia (ventilated), fungal sinusitis, burns plus COVID-19, and two non-hospitalized patients with COVID-19 received nebulized nanosilver solution.Nanosilver solutions demonstrated pH-dependent antimicrobial efficacy;reduced infection and inflammation without evidence of lung toxicity in the rat model;and inactivated HSV-1 and SARS-CoV-2. Pneumonia patients had rapidly reduced pulmonary symptoms, recovering pre-illness respiratory function. Fungal sinusitis-related inflammation decreased immediately with infection clearance within 21 days. Non-hospitalized patients with COVID-19 experienced rapid symptom remission.Nanosilver solutions, due to anti-inflammatory, antiviral, and antimicrobial activity, may be effective for treating respiratory inflammation and infections caused by viruses and/or microbes.